Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 57

1.

Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072.

Benson C, Ray-Coquard I, Sleijfer S, Litière S, Blay JY, Le Cesne A, Papai Z, Judson I, Schöffski P, Chawla S, Gil T, Piperno-Neumann S, Marréaud S, Dewji MR, van der Graaf WT.

Gynecol Oncol. 2016 Mar 21. pii: S0090-8258(16)30079-8. doi: 10.1016/j.ygyno.2016.03.024. [Epub ahead of print]

PMID:
27012429
2.

TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.

Quoix E, Lena H, Losonczy G, Forget F, Chouaid C, Papai Z, Gervais R, Ottensmeier C, Szczesna A, Kazarnowicz A, Beck JT, Westeel V, Felip E, Debieuvre D, Madroszyk A, Adam J, Lacoste G, Tavernaro A, Bastien B, Halluard C, Palanché T, Limacher JM.

Lancet Oncol. 2016 Feb;17(2):212-23. doi: 10.1016/S1470-2045(15)00483-0. Epub 2015 Dec 23.

PMID:
26727163
3.

First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial.

Chawla SP, Papai Z, Mukhametshina G, Sankhala K, Vasylyev L, Fedenko A, Khamly K, Ganjoo K, Nagarkar R, Wieland S, Levitt DJ.

JAMA Oncol. 2015 Dec;1(9):1272-80. doi: 10.1001/jamaoncol.2015.3101.

PMID:
26378637
4.

Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials.

Duffaud F, Sleijfer S, Litière S, Ray-Coquard I, Le Cesne A, Papai Z, Judson I, Schöffski P, Chawla SP, Dewji R, Marreaud S, Verweij J, van der Graaf WT.

Eur J Cancer. 2015 Nov;51(17):2615-23. doi: 10.1016/j.ejca.2015.08.002. Epub 2015 Aug 25.

PMID:
26321011
5.

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.

Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, Krailo MD, Gebhardt M, Pápai Z, Meyer J, Nadel H, Randall RL, Deffenbaugh C, Nagarajan R, Brennan B, Letson GD, Teot LA, Goorin A, Baumhoer D, Kager L, Werner M, Lau CC, Sundby Hall K, Gelderblom H, Meyers P, Gorlick R, Windhager R, Helmke K, Eriksson M, Hoogerbrugge PM, Schomberg P, Tunn PU, Kühne T, Jürgens H, van den Berg H, Böhling T, Picton S, Renard M, Reichardt P, Gerss J, Butterfass-Bahloul T, Morris C, Hogendoorn PC, Seddon B, Calaminus G, Michelagnoli M, Dhooge C, Sydes MR, Bernstein M; EURAMOS-1 investigators.

J Clin Oncol. 2015 Jul 10;33(20):2279-87. doi: 10.1200/JCO.2014.60.0734. Epub 2015 Jun 1.

PMID:
26033801
6.

Optimal line of hepatotomy for left lateral living donor liver transplantation according to the anatomical variations of left hepatic duct system.

Kiss M, Deshpande RR, Nemeskéri Á, Nguyen TT, Kürti Z, Kovács S, Pápai Z, Németh K, Szuák A, Dudás I, Kóbori L.

Pediatr Transplant. 2015 Aug;19(5):510-6. doi: 10.1111/petr.12468. Epub 2015 Apr 23.

PMID:
25907302
7.

Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial.

Blay JY, Shen L, Kang YK, Rutkowski P, Qin S, Nosov D, Wan D, Trent J, Srimuninnimit V, Pápai Z, Le Cesne A, Novick S, Taningco L, Mo S, Green S, Reichardt P, Demetri GD.

Lancet Oncol. 2015 May;16(5):550-60. doi: 10.1016/S1470-2045(15)70105-1. Epub 2015 Apr 14.

8.

Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial.

Blay JY, Pápai Z, Tolcher AW, Italiano A, Cupissol D, López-Pousa A, Chawla SP, Bompas E, Babovic N, Penel N, Isambert N, Staddon AP, Saâda-Bouzid E, Santoro A, Franke FA, Cohen P, Le-Guennec S, Demetri GD.

Lancet Oncol. 2015 May;16(5):531-40. doi: 10.1016/S1470-2045(15)70102-6. Epub 2015 Apr 8.

PMID:
25864104
9.

[Rare hereditary tumours].

Nagy P, Lahm E, Pápai Z.

Magy Onkol. 2014 Jun;58(2):94-7. Epub 2013 Nov 10. Hungarian.

10.

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.

André F, O'Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, Masuda N, Wilks S, Arena F, Isaacs C, Yap YS, Papai Z, Lang I, Armstrong A, Lerzo G, White M, Shen K, Litton J, Chen D, Zhang Y, Ali S, Taran T, Gianni L.

Lancet Oncol. 2014 May;15(6):580-91. doi: 10.1016/S1470-2045(14)70138-X. Epub 2014 Apr 14.

PMID:
24742739
11.

[Medical treatment of soft tissue sarcomas based on the histological subtype].

Pápai Z.

Magy Onkol. 2014 Mar;58(1):53-8. Epub 2014 Feb 1. Review. Hungarian.

12.

[Surgical treatment of retroperitoneal sarcomas].

Bursics A, Besznyák I, Mersich T, Pörneczi B, Dede K, Papp G, Ágoston P, Pápai Z.

Magy Onkol. 2014 Mar;58(1):47-51. Epub 2014 Feb 12. Review. Hungarian.

13.

[Resection and reconstruction in cases of musculosceletal soft tissue sarcomas].

Antal I, Kiss J, Perlaky T, Szalay K, Vancsó P, Oláh Z, Sápi Z, Pápai Z, Szendrői M.

Magy Onkol. 2014 Mar;58(1):32-6. Epub 2014 Mar 1. Review. Hungarian.

14.

Mass spectrometric identification of ancient proteins as potential molecular biomarkers for a 2000-year-old osteogenic sarcoma.

Bona A, Papai Z, Maasz G, Toth GA, Jambor E, Schmidt J, Toth C, Farkas C, Mark L.

PLoS One. 2014 Jan 27;9(1):e87215. doi: 10.1371/journal.pone.0087215. eCollection 2014. Erratum in: PLoS One. 2014;9(7):e103862.

15.

[Treatment of metastatic midgut neuroendocrine tumour associated with carcinoid syndrome].

Uhlyarik A, Lahm E, Vachaja J, Pápai Z.

Orv Hetil. 2014 Feb 1;155(5):194-8. doi: 10.1556/OH.2014.29818. Hungarian.

PMID:
24463166
16.

[Our experience with targeted therapy in glioblastoma multiforme].

Kiss E, Lahm E, Vachaja J, Nagy P, Bazsó P, Fekete Z, Takácsi-Nagy Z, Pápai Z.

Magy Onkol. 2013 Dec;57(4):264-8. doi: MagyOnkol.2013.57.4.264. Epub 2013 Nov 1. Hungarian.

17.

[Diagnosis and treatment options of neuroendocrine tumours].

Uhlyarik A, Pápai Z.

Orv Hetil. 2013 Sep 29;154(39):1549-55. doi: 10.1556/OH.2013.29716. Review. Hungarian.

PMID:
24058100
18.

Poorly differentiated synovial sarcoma is associated with high expression of enhancer of zeste homologue 2 (EZH2).

Changchien YC, Tátrai P, Papp G, Sápi J, Fónyad L, Szendrői M, Pápai Z, Sápi Z.

J Transl Med. 2012 Oct 30;10:216. doi: 10.1186/1479-5876-10-216.

19.

Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.

Modest DP, Brodowicz T, Stintzing S, Jung A, Neumann J, Laubender RP, Ocvirk J, Kurteva G, Papai Z, Knittelfelder R, Kirchner T, Heinemann V, Zielinski CC.

Oncology. 2012;83(5):241-7. Epub 2012 Aug 29.

PMID:
22948721
20.

Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial.

Scagliotti GV, Krzakowski M, Szczesna A, Strausz J, Makhson A, Reck M, Wierzbicki RF, Albert I, Thomas M, Miziara JE, Papai ZS, Karaseva N, Thongprasert S, Portulas ED, von Pawel J, Zhang K, Selaru P, Tye L, Chao RC, Govindan R.

J Clin Oncol. 2012 Jun 10;30(17):2070-8. doi: 10.1200/JCO.2011.39.2993. Epub 2012 May 7.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk